CD157: From Myeloid Cell Differentiation Marker to Therapeutic Target in Acute Myeloid Leukemia
| Autor: | Stefania Augeri, Ada Funaro, Erika Ortolan, Giulia Fissolo, Silvia Peola, Daniela Bellarosa, Monica Binaschi, Enza Ferrero, Cristiano Bracci, Andrea Pellacani, Yuliya Yakymiv |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Models
Molecular Myeloid Protein Conformation medicine.medical_treatment Review Biology CD38 acute myeloid leukemia MEN1112/OBT357 Adaptive Immunity GPI-Linked Proteins Targeted therapy Substrate Specificity cyclic ADPR Structure-Activity Relationship Antineoplastic Agents Immunological Antigen Myeloid Cell Differentiation stem cells Antigens CD Gene duplication medicine Biomarkers Tumor Humans Myeloid Cells Tissue Distribution Molecular Targeted Therapy ADP-ribosyl Cyclase CD157/BST-1 cell adhesion myeloid cells therapeutic defucosylated monoclonal antibody Myeloid leukemia General Medicine Immunity Innate Enzyme Activation Leukemia Myeloid Acute medicine.anatomical_structure Cancer research Disease Susceptibility Stem cell |
| Zdroj: | Cells |
| ISSN: | 2073-4409 |
| Popis: | Human CD157/BST-1 and CD38 are dual receptor-enzymes derived by gene duplication that belong to the ADP ribosyl cyclase gene family. First identified over 30 years ago as Mo5 myeloid differentiation antigen and 10 years later as Bone Marrow Stromal Cell Antigen 1 (BST-1), CD157 proved not to be restricted to the myeloid compartment and to have a diversified functional repertoire ranging from immunity to cancer and metabolism. Despite being a NAD+-metabolizing ectoenzyme anchored to the cell surface through a glycosylphosphatidylinositol moiety, the functional significance of human CD157 as an enzyme remains unclear, while its receptor role emerged from its discovery and has been clearly delineated with the identification of its high affinity binding to fibronectin. The aim of this review is to provide an overview of the immunoregulatory functions of human CD157/BST-1 in physiological and pathological conditions. We then focus on CD157 expression in hematological tumors highlighting its emerging role in the interaction between acute myeloid leukemia and extracellular matrix proteins and its potential utility for monoclonal antibody targeted therapy in this disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |